sc-205299

PAF analog containing docosahexaenoate at the sn-2 position rather than the acetate moiety found in PAF C-16. Docosahexaenoyl PAF C-16 can be oxidatively fragmented, with the result of the production of phospholipids with PAF-like activity.1,2

1 mg/10 mg

sc-221638

A novel immune modulator that inhibits lymphocyte emigration from lymphoid organs; acts as a potent agonist at four of the five sphingosine-1-phosphate (S1P) receptors.

500 µg/1 mg

sc-205342

PAF analog with mixed antagonist/agonist properties. In human monocyte-derived macrophages, it is an antagonist which inhibits the production of reactive oxygen species in response to PAF C-16.1 In rabbit platelets and guinea pig macrophages, hexanolamino PAF C-16 is a partial agonist, and in guinea pig platelets it is a full agonist.2

1 mg/10 mg

sc-205420

An inhibitor of PLA2 with an IC₅₀ value of 6.2 µM for porcine pancreatic PLA2.

1 mg/5 mg

sc-205087

A synthetic PAF analog; has been shown to decrease plasma membrane fluidity and inhibit tumor cell invasiveness in embryonic chick heart.

5 mg/10 mg

sc-220757

A synthetic PAF analog; a less potent agonist than methylcarbamyl PAF C-16 in induction of platelet aggregation in both human and rabbit PRP.

5 mg/10 mg

sc-222178

A component of membrane-bound receptors in association with phospholipase C (PLC). Stimulates brain phospholipase D (PLD) activity in vitro. Has been shown to activate protein kinase C (PKC) in the presence of phosphatidyl serine and Ca²⁺. Antagonist of ATP-sensitive potassium (KATP) channels when applied to inside-out membrane patches.

100 µg

sc-200867

The phospolipase A2 activating protein (PLAP) is a 21-residue fragment that spans the PLAP-melittin homology sequence and is a member of the β-transducin (Gβ) superfamily.

100 µg/1 mg

sc-296161

The group IVA phospholipase A2 (PLA2α), known as calcium dependent cytosolic PLA2α (cPLA2α), selectively releases arachidonic acid (AA) from membrane phospholipids, playing a central role in initiating the synthesis of prostaglandins (PGs) and leukotrienes (LTs). Pyrrophenone inhibits cPLA2α with an IC50 of 4. nM in enzyme assays and potently blocks the release of AA and the production of PGE2 and LTC4 in cells (IC50 = 24, 25, and 14 nM, respectively). Its action is reversible and selective, as pyrrophenone inhibits the secretory type IB and IIA PLA2s with more than a hundred-fold less potency. Pyrrophenone has also been shown to inhibit calcium ionophore (A23187)-stimulated AA release from monocytic cells, interleukin-1-induced PGE2 synthesis in mesangial cells, and the production of PGE2, LTs, and platelet-activating factor by human neutrophils always with maximal inhibition at concentrations below 1 μM.

500 µg/1 mg

sc-205093

An isosteric analog of PAF, while it is also a synthetic analog which contains an acetyl group attached by a thioester bond at the sn-2 position. It functions as a PAF receptor agonist, and its potency is comparable to PAF C-18 in rabbit platelet aggregation, and to PAF C-16 in the activation of guinea pig macrophages. A substrate for lysophospholipase II and for PAF-AH.

5 mg/10 mg

sc-363292

This product is known to be a selective and potent inhibitor of phospholipase D2 that shows a 75-fold selectivity against PLD1.

10 mg/50 mg